Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (11)
Type
(
1 selected
)
Type
Guidance (304)
Quality standard (31)
Guidance programme
Guidance programme
Diagnostics guidance (1)
Health technology evaluations (6)
Highly specialised technologies guidance (1)
Interventional procedures guidance (6)
Medical technologies guidance (5)
Technology appraisal guidance (285)
Apply filters
Showing 171 to 180 of 304
Type: Guidance
Remove Type: Guidance filter
Guidance and quality standards awaiting development
Title
Type
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over ID 6475
Technology appraisal guidance
Obicetrapib or obicetrapib–ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia TS ID 12103
Technology appraisal guidance
Obinutuzumab for treating lupus nephritis ID 6420
Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy TSID 11996
Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]
Technology appraisal guidance
Ondansetron for treating alcohol-use disorder TS ID 11884
Technology appraisal guidance
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941
Technology appraisal guidance
Oral semaglutide for managing overweight and obesity [ID6188]
Technology appraisal guidance
Orforglipron for managing overweight and obesity TS ID 12102
Technology appraisal guidance
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer ID 6472
Technology appraisal guidance
Previous page
1
…
16
17
Current page
18
19
20
…
31
Page
18
of
31
Next page
Results per page
10
25
50
All
Back to top